HL-085 in NRAS-mutated Advanced Melanoma
NCT05217303
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
100
Enrollment
INDUSTRY
Sponsor class
Conditions
Melanoma
Interventions
DRUG:
HL-085
Sponsor
Shanghai Kechow Pharma, Inc.